Orgenesis Inc. EPS (Basic)

EPS (Basic) of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Basic) growth rates and interactive chart. Basic earnings per share (EPS) tells investors how much of a firm's net income was allotted to each share of common stock. It is reported in a company's income statement and is especially informative for businesses with only common stock in their capital structures. Calculated as net income to common divided by the weighted average number of basic shares outstanding (doesn't take into account potential dilution from options or share issuance).

Highlights and Quick Summary

  • EPS (Basic) for the quarter ending September 29, 2021 was 0.42 (a 281.82% increase compared to previous quarter)
  • Year-over-year quarterly EPS (Basic) decreased by -119.63%
  • Annual EPS (Basic) for 2020 was 0.29 (a -116.38% decrease from previous year)
  • Annual EPS (Basic) for 2019 was -1.77 (a 23.78% increase from previous year)
  • Annual EPS (Basic) for 2018 was -1.43 (a 9.16% increase from previous year)
  • Twelve month EPS (Basic) ending September 29, 2021 was -1.62 (a -24.65% decrease compared to previous quarter)
  • Twelve month trailing EPS (Basic) decreased by -155.29% year-over-year
Trailing EPS (Basic) for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-1.62 -2.15 -1.31 2.93
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Basic) of Orgenesis Inc.

Most recent EPS (Basic)of ORGS including historical data for past 10 years.

Interactive Chart of EPS (Basic) of Orgenesis Inc.

Orgenesis Inc. EPS (Basic) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.42 0.11 -0.01
2020 -2.14 -0.11 0.95 4.23 0.29
2019 -0.42 0.44 0.36 0.55 -1.77
2018 -0.39 -1.43
2017 -1.31
2016 -1.3

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.